MEHMO Natural History and Biomarkers

Obesity Clinical Trial

Official title:

Investigations of Individuals With MEHMO Syndrome or eIF2-Pathway Related Conditions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06019182
• Other study ID #: 10001681
• Secondary ID: 001681-CH
• Status: Recruiting
• Start date: May 19, 2024
• Est. completion date: September 1, 2053

Study information

• Verified date: December 6, 2023
• Source: National Institutes of Health Clinical Center (CC)
• Contact: An N Dang Do, M.D.
• Phone: (301) 496-8849
• Email: an.dangdo[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined outcome measures. This protocol seeks to identify biochemical and clinical markers to monitor disease progression, and better understand the natural history of these conditions. Any person diagnosed with MEHMO syndrome or related conditions, who can travel to the NIH Clinical Center can participate in this study. The study involves: - General health assessment and evaluation - Imaging studies - Laboratory tests - Collection of blood, urine, spinal fluid, skin biopsy.

Description:

Study Description: This is a prospective natural history study of individuals who have MEHMO syndrome or eIF2-pathway related conditions, or who are carriers of EIF2S3-related conditions to generate hypotheses for further understanding of disease pathophysiology, diagnosis, prognosis, management, and treatment. The protocol aims to enroll and follow affected or carrier individuals longitudinally to establish a repository of concurrent evaluations and biomaterials, as well as to enroll unaffected individuals for collection of informative comparable data and samples. Objectives: Primary Objective: Characterize the presentation of MEHMO syndrome and eIF2 pathway related conditions. Secondary Objectives: 1. Identify disease-reflective fluid biomarkers 2. Develop a disease severity rating scale or classification algorithm 3. Assess tolerability and feasibility of study evaluations 4. Establish a repository of participant data and samples for future research Endpoints: Primary Endpoint: Frequency and time-to-event of signs and symptoms. Secondary Endpoints: 1. Mean difference of candidate fluid biomarkers level in affected versus carrier versus unaffected individuals 2. Correlation of rating scale or classification algorithm to age, genotype, or other variables 3. Frequency of completed evaluations and reasons for Noncompletion Study Population: 25 affected individuals 1-week of age or older 25 EIF2S3-variant carrier individuals 1-month of age or older 50 unaffected individuals 1 month of age or older of any sex, race, ethnicity, geographic location who can participate without increased risk to personal health.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 1, 2053
• Est. primary completion date: September 1, 2053
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Week to 100 Years

Eligibility

• Inclusion Criteria To be eligible to participate in this study, an individual must meet the following criteria: Be greater than or equal to 1-week of age if affected, or greater than or equal to 1-month of age if unaffected. 19 For Screening: Have a combination of signs/symptoms suggestive of MEHMO syndrome, AND no or inconclusive molecular testing. For Main Study

1. Have a combination of signs/symptoms suggestive of MEHMO syndrome, AND disease-associated variant(s) or variant(s) of uncertain significance in one of the eIF2- pathway related genes OR

2. Be a first-degree relative of an individual with EIF2S3-related MEHMO syndrome, AND a carrier of the pathogenic or likely pathogenic variant. OR

3. Be a non-affected, non-carrier family member of an individual with MEHMO syndrome or an eIF2-pathway related condition. Exclusion Criteria Any individual who, in the opinion of the Investigators, is unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation will be excluded from participation in this study.

Related Conditions & MeSH terms

• Epilepsy
• Hypogonadism
• Intellectual Disability
• Microcephaly
• Nervous System Malformations
• Obesity

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize the presentation of MEHMO syndrome and eIF2-pathway related conditions.	Frequency and time-to-event of signs and symptoms. These will allow systematic and potentially quantitative measures of disease presentation that can then be operationalized to develop disease rating scale(s) and correlative measures for candidate biomarkers.	Ongoing
Secondary	Identify disease-reflective fluid biomarkers	Difference and range of candidate fluid biomarkers level in affected vs. carrier vs. unaffected individuals. Sensitive or specific quantitative markers will allow for improved diagnosis, management, and treatment of MEHMO syndrome or eIF2-pathway related disorders.	Ongoing
Secondary	Develop a disease severity rating scale or classification algorithm.	A quantitative rating scale or classification algorithm that reflects other disease aspects will provide a standardized tool for communication amongst all involved in the clinical care and research of MEHMO syndrome or eIF2-pathway related disorders.	Ongoing
Secondary	Assess tolerability and feasibility of study evaluations.	Frequency of completed evaluations and reasons for non-completion will inform design of future trials for MEHMO syndrome or eIF2-pathway related disorders.	Ongoing
Secondary	Characterize EIF2S3-carrier phenotype.	Frequency and time-to-event of signs and symptoms at disease-relevant intervals will provide a systematic evaluation of EIF2S3- carrier phenotype.	Ongoing
Secondary	Establish a repository of participant data and samples for future research.	A repository of concurrently collected participant data and samples for future research will provide resources for future research towards understanding the disease and developing interventions.	Ongoing

External Links

•   NIH Clinical Center Detailed Web Page